The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Danish drugmaker Novo Nordisk has launched its popular weight-loss drug Wegovy in India, months after its rival Mounjaro’s ...

Wegovy, which is a prescription medicine is indicated to help manage weight and lower the risk of serious heart-related ...

Novo Nordisk has introduced Wegovy, a once-weekly weight loss injection, in India. The drug aims to manage obesity and reduce ...

Wegovy, a weight-loss injection containing semaglutide, has arrived in India, offering a new approach to combatting obesity ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...